# Michel Finance

> Michel Finance is a Series B investor at Truffle Capital backing Marketing and Biotechnology. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Truffle Capital](https://shizune.co/investors/profile/truffle-capital)
- Location: Paris, France
- Total investments: 2
- Last investment: Jun 2005
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/michel-finance/1/2a/973

Michel Finance is a Series B investor at Truffle Capital in Paris focused on Marketing and Biotechnology. Michel is CEO and Board member of Theradiag, a company specialized in biotherapy monitoring and diagnostic.Prior to joining Theradiag, Michel was executive VP of Neovacs and Flamel Technologies, both biotech companies listed on Alternext and Nasdaq respectively, CEO of Carmat, an innovative company developing a total artificial heart and listedon Alternext and co-founded by Truffle Capital, Senior Vice President of the Aventis Group, one of the leading pharmaceutical companies in the world, and Senior Vice President and CFO of Sanofi Pasteur, a world leader in vaccines.Michel is also a Director of France Biotech, the French association of entrepreneurs in the biotech sector, and of Carmat and Neovacs.Michel graduated from EM Lyon and is a Certfied Public Accountant. Chevalier de l’ordre national du Mérite.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Marketing | 1 | 50% |
| Biotechnology | 1 | 50% |
| Manufacturing | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 50% |
| Series C | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Theradiag | Theradiag is a France-based company which develops and markets biological diagnostic tools. The company develops and offers product panels for diagnosing autoimmune diseases, allergies, and infectious diseases. | $5.5M | Series C | Jun 02, 2005 |  |
| Theradiag | Theradiag is a France-based company which develops and markets biological diagnostic tools. The company develops and offers product panels for diagnosing autoimmune diseases, allergies, and infectious diseases. | $10.2M | Series B | May 01, 2003 |  |

2 of 2 investments shown.

## Co-investors
- [123Venture](https://shizune.co/investors/profile/123venture) — VC Fund, 1 deal together
- [Auriga Partners](https://shizune.co/investors/profile/auriga-partners) — VC Fund, 1 deal together
- [Siparex Groupe](https://shizune.co/investors/profile/groupe-siparex) — VC Fund, 1 deal together
- [Idinvest Partners](https://shizune.co/investors/profile/idinvest-partners) — VC Fund, 1 deal together
- [Ventech](https://shizune.co/investors/profile/ventech-capital) — VC Fund, 1 deal together

## About Truffle Capital

VC Fund · Paris, France

Truffle Capital is an independent, European venture capital firm focused on disruptive technologies in IT (FinTech and InsurTech) and Life Sciences (BioTech and MedTech). Truffle Capital aims to support the creation and growth of young innovative companies with the potential to become tomorrow’s market leaders. Chaired by Patrick Kron, alongsidethe company’s founders and CEOs, Philippe Pouletty and Bernard-Louis Roques, Truffle Capital raised over $1 billion and has supported over 75 companies since its creation, in the digital technologies and life sciences sectors.At the end of 2017, Truffle Capital successfully completed the first close of its two new institutional funds, Truffle Financial Innovation Fund and Truffle BioMedTech Fund, as well as the first close of a fund dedicated to the French Reserve Fund (« Fonds de Réserve pour les Retraites » or « FRF »).On May 2019, Truffle Capital is a company of 24 professionals from various nationalities (French, Italian, English, Chinese…), passionated by the trade of financing innovation.

5 contacts available at Truffle Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Antoine Pau | Partner | https://shizune.co/investors/profile/antoine-pau |
| Faranaz Auliar | Philippe Pouletty Executive Assistant | https://shizune.co/investors/profile/faranaz-auliar |
| Jean-Claude Caducal | CEO Circle, Life Sciences | https://shizune.co/investors/profile/jean-claude-caducal |
| Michel Finance | Venture Partner | https://shizune.co/investors/profile/michel-finance |
| Miguel Sieler | Venture Partner | https://shizune.co/investors/profile/miguel-sieler |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Michel Finance invest in?

Michel Finance invests primarily in Marketing, Biotechnology and Manufacturing startups, most often at Series B and Series C stage. Most of the 2 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Michel Finance last invest?

The most recent investment recorded for Michel Finance closed in Jun 2005. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co